144 related articles for article (PubMed ID: 27595248)
1. [Effectivity and security of vildagliptin as additional treatment for Type 2 diabetes mellitus in real-life conditions in Mexico. EDGE Study subanalysis].
Márquez-Rodríguez E; Brea-Andrea E; Rajmet-Hace VA; Salinas-Salinas J; Mariño-Rojas F
Gac Med Mex; 2016; 152(4):457-64. PubMed ID: 27595248
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study.
Mendivil CO; Márquez-Rodríguez E; Angel ID; Paz G; Rodríguez C; Almada J; Szyskowsky O
Curr Med Res Opin; 2014 Sep; 30(9):1769-76. PubMed ID: 24867177
[TBL] [Abstract][Full Text] [Related]
6. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
7. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
Hoste J; Daci E; Mathieu C
Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
Brath H; Bialek C; Gingl E; Resl M; Prager R; Ratzinger M
Wien Klin Wochenschr; 2015 Apr; 127(7-8):250-5. PubMed ID: 25576329
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
15. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
17. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
Shelbaya S; Rakha S
Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
